Literature DB >> 22555661

Is targeting of CD47-SIRPα enough for treating hematopoietic malignancy?

Xi Wen Zhao, Taco W Kuijpers, Timo K van den Berg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22555661     DOI： 10.1182/blood-2011-11-391367

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  On the mechanism and benefit of siRNA-mediated targeting of CD47 in cancer.

Authors:  Xiwen Zhao; Hanke Matlung; Taco W Kuijpers; Timo K van den Berg
Journal:  Mol Ther       Date:  2013-10       Impact factor: 11.454

2.  On the mechanism of CD47 targeting in cancer.

Authors:  Xi Wen Zhao; Hanke L Matlung; Taco W Kuijpers; Timo K van den Berg
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-24       Impact factor: 11.205

3.  Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy.

Authors:  Tadahiko Yanagita; Yoji Murata; Daisuke Tanaka; Sei-Ichiro Motegi; Eri Arai; Edwin Widyanto Daniwijaya; Daisuke Hazama; Ken Washio; Yasuyuki Saito; Takenori Kotani; Hiroshi Ohnishi; Per-Arne Oldenborg; Noel Verjan Garcia; Masayuki Miyasaka; Osamu Ishikawa; Yae Kanai; Takahide Komori; Takashi Matozaki
Journal:  JCI Insight       Date:  2017-01-12

Review 4.  Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47.

Authors:  David R Soto-Pantoja; Erica V Stein; Natasha M Rogers; Maryam Sharifi-Sanjani; Jeffrey S Isenberg; David D Roberts
Journal:  Expert Opin Ther Targets       Date:  2012-10-27       Impact factor: 6.902

Review 5.  Insights into CD47/SIRPα axis-targeting tumor immunotherapy.

Authors:  Xuyao Zhang; Jiajun Fan; Dianwen Ju
Journal:  Antib Ther       Date:  2018-08-28

Review 6.  Engineering macrophages to phagocytose cancer cells by blocking the CD47/SIRPɑ axis.

Authors:  Hongcheng Yang; Ruoyang Shao; Hongxin Huang; Xinlong Wang; Zhili Rong; Ying Lin
Journal:  Cancer Med       Date:  2019-06-11       Impact factor: 4.452

Review 7.  Targeting the CD47-SIRPα Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils.

Authors:  Leonie M Behrens; Timo K van den Berg; Marjolein van Egmond
Journal:  Cancers (Basel)       Date:  2022-07-11       Impact factor: 6.575

Review 8.  CD47 as a promising therapeutic target in oncology.

Authors:  Hai Zhao; Shuangshuang Song; Junwei Ma; Zhiyong Yan; Hongwei Xie; Ying Feng; Shusheng Che
Journal:  Front Immunol       Date:  2022-08-22       Impact factor: 8.786

9.  Disruption of SIRPα signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts.

Authors:  Alexandre P A Theocharides; Liqing Jin; Po-Yan Cheng; Tatiana K Prasolava; Andrei V Malko; Jenny M Ho; Armando G Poeppl; Nico van Rooijen; Mark D Minden; Jayne S Danska; John E Dick; Jean C Y Wang
Journal:  J Exp Med       Date:  2012-09-03       Impact factor: 14.307

10.  Thrombospondin-1 signaling through CD47 inhibits self-renewal by regulating c-Myc and other stem cell transcription factors.

Authors:  Sukhbir Kaur; David R Soto-Pantoja; Erica V Stein; Chengyu Liu; Abdel G Elkahloun; Michael L Pendrak; Alina Nicolae; Satya P Singh; Zuqin Nie; David Levens; Jeffrey S Isenberg; David D Roberts
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.